Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Control Bionics Ltd. ( (AU:CBL) ).
Control Bionics Limited has announced the integration of Apple’s new Brain-Computer Interface (BCI) Human Interface Device protocol into its AAC solutions, enhancing user interaction with Apple devices through neural and motion-based input. This integration simplifies device setup, improves neural feedback, and enables automatic activation of communication tools, thereby strengthening the company’s position in the AAC market and empowering users with disabilities to communicate more effectively.
More about Control Bionics Ltd.
Control Bionics Limited is a global leader in augmentative and alternative communication (AAC) technology, focusing on providing solutions for individuals with severe speech and physical impairments. The company is known for its NeuroNode® and NeuroNode Trilogy® product lines and has a strong market presence with funding approvals in the United States and Australia.
Average Trading Volume: 306,434
Technical Sentiment Signal: Sell
Current Market Cap: A$14.14M
Find detailed analytics on CBL stock on TipRanks’ Stock Analysis page.